Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Europe is a growing market as growing obesity rates are leading to an increase in acceptance of GLP-1 therapies and an increased focus on integrated care solutions that include nutrition support and lifestyle support
Vehicle (n=11)
Clinical Evidence and Ongoing Trials A 2023 Phase 2 trial in the New England Journal of Medicine reported approximately 24% mean body weight reduction at 48 weeks with the 12 mg dose
Scientifically Formulated for Results: Each serving of Vivaravida BC-159 delivers a powerful combination of 1500 mcg of our advanced 159 Peptide Blend, 400 mg of Collagen Peptides, 400 mg of Creatine, and 200 mg of Magnesium Glycinate
